心血管代謝疾患の市場規模は、2022 年に 1,253 ドルと評価されました。この市場は、2023 年の 1,553 億 7000 万ドルから 2032 年までに 8,684 億 5,000 万ドルに成長すると予測され、予測期間中(2023 - 2032)のCAGRは 24.00% と推定されます。急速に変化するライフスタイルと、糖尿病、高血圧、心血管疾患、高コレステロールなどの有病率の増加が、市場の成長を促進する主な要因です。
目次
TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT
6.1. Overview
6.2. Angiotensin-converting Enzyme (ace) Inhibitors
6.3. Diuretics
6.4. Glucophage
6.5. Others
7. GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.2. Hospital Pharmacies
7.3. Retail Pharmacies
7.4. Online Pharmacies
7.5. Others
8. GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY REGION
8.1. Overview
1.1. North America
1.1.1. US
1.1.2. Canada
1.2. Europe
1.2.1. Germany
1.2.2. France
1.2.3. UK
1.2.4. Italy
1.2.5. Spain
1.2.6. Rest of Europe
1.3. Asia-Pacific
1.3.1. China
1.3.2. India
1.3.3. Japan
1.3.4. South Korea
1.3.5. Australia
1.3.6. Rest of Asia-Pacific
1.4. Rest of the World
1.4.1. Middle East
1.4.2. Africa
1.4.3. Latin America
2. COMPETITIVE LANDSCAPE
2.1. Overview
2.2. Competitive Analysis
2.3. Market Share Analysis
2.4. Major Growth Strategy in the Global Cardiometabolic Disease Market,
2.5. Competitive Benchmarking
2.6. Leading Players in Terms of Number of Developments in the Global Cardiometabolic Disease Market,
2.7. Key developments and Growth Strategies
2.7.1. New Product Launch/Service Deployment
2.7.2. Merger & Acquisitions
2.7.3. Joint Ventures
2.8. Major Players Financial Matrix
2.8.1. Sales & Operating Income, 2022
2.8.2. Major Players R&D Expenditure. 2022
3. COMPANY PROFILES
3.1. Cardax, Inc.
3.1.1. Company Overview
3.1.2. Financial Overview
3.1.3. Products Offered
3.1.4. Key Developments
3.1.5. SWOT Analysis
3.1.6. Key Strategies
3.2. Novartis AG
3.2.1. Company Overview
3.2.2. Financial Overview
3.2.3. Products Offered
3.2.4. Key Developments
3.2.5. SWOT Analysis
3.2.6. Key Strategies
3.3. Novo Nordisk A/S
3.3.1. Company Overview
3.3.2. Financial Overview
3.3.3. Products Offered
3.3.4. Key Developments
3.3.5. SWOT Analysis
3.3.6. Key Strategies
3.4. Eli Lilly and Company
3.4.1. Company Overview
3.4.2. Financial Overview
3.4.3. Products Offered
3.4.4. Key Developments
3.4.5. SWOT Analysis
3.4.6. Key Strategies
3.5. Bayer AG
3.5.1. Company Overview
3.5.2. Financial Overview
3.5.3. Products Offered
3.5.4. Key Developments
3.5.5. SWOT Analysis
3.5.6. Key Strategies
3.6. Allergan
3.6.1. Company Overview
3.6.2. Financial Overview
3.6.3. Products Offered
3.6.4. Key Developments
3.6.5. SWOT Analysis
3.6.6. Key Strategies
3.7. Boehringer Ingelheim International GmbH
3.7.1. Company Overview
3.7.2. Financial Overview
3.7.3. Products Offered
3.7.4. Key Developments
3.7.5. SWOT Analysis
3.7.6. Key Strategies
3.8. ASTRAZENECA
3.8.1. Company Overview
3.8.2. Financial Overview
3.8.3. Products Offered
3.8.4. Key Developments
3.8.5. SWOT Analysis
3.8.6. Key Strategies
4. APPENDIX
4.1. References
4.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL CARDIOMETABOLIC DISEASE MARKET, SYNOPSIS, 2018-2032
TABLE 2 GLOBAL CARDIOMETABOLIC DISEASE MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)
TABLE 3 GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 5 NORTH AMERICA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 7 US: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 8 US: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 9 CANADA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 10 CANADA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 1 EUROPE: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 2 EUROPE: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 3 GERMANY: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 4 GERMANY: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 5 FRANCE: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 6 FRANCE: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 7 ITALY: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 8 ITALY: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 9 SPAIN: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 10 SPAIN: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 11 UK: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 12 UK: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 13 REST OF EUROPE: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 14 REST OF EUROPE: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 15 ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 16 ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 17 JAPAN: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 18 JAPAN: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 19 CHINA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 20 CHINA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 21 INDIA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 22 INDIA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 23 AUSTRALIA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 24 AUSTRALIA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 25 SOUTH KOREA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 26 SOUTH KOREA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 27 REST OF ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 28 REST OF ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 29 REST OF THE WORLD: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 30 REST OF THE WORLD: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 31 MIDDLE EAST: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 32 MIDDLE EAST: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 33 AFRICA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 34 AFRICA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 35 LATIN AMERICA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 36 LATIN AMERICA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CARDIOMETABOLIC DISEASE MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CARDIOMETABOLIC DISEASE MARKET
FIGURE 4 GLOBAL CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY TREATMENT, 2022
FIGURE 5 GLOBAL CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2022
FIGURE 6 GLOBAL CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 7 NORTH AMERICA: CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 8 EUROPE: CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 REST OF THE WORLD: CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 GLOBAL CARDIOMETABOLIC DISEASE MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 12 CARDAX, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 CARDAX, INC.: SWOT ANALYSIS
FIGURE 14 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 NOVARTIS AG: SWOT ANALYSIS
FIGURE 16 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 NOVO NORDISK A/S: SWOT ANALYSIS
FIGURE 18 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 ELI LILLY AND COMPANY: SWOT ANALYSIS
FIGURE 20 BAYER AG.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 BAYER AG.: SWOT ANALYSIS
FIGURE 22 ALLERGAN: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 ALLERGAN: SWOT ANALYSIS
FIGURE 24 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SWOT ANALYSIS
FIGURE 26 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 ASTRAZENECA: SWOT ANALYSIS
